Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Volume 62, Issue 20
Displaying 1-31 of 31 articles from this issue
EDITORIAL
ORIGINAL ARTICLES
  • Tsukasa Ikeura, Takashi Tomiyama, Ayaka Takaori, Takashi Ito, Koh Naka ...
    2023 Volume 62 Issue 20 Pages 2931-2940
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    Objective Steroid pulse therapy is a regimen involving the intravenous administration of supra-pharmacological doses of corticosteroids in the short term. It is used to treat various inflammatory and autoimmune conditions. However, the strengths and limitations of steroid pulse therapy for induction of remission in type 1 autoimmune pancreatitis (AIP) are unknown.

    Methods Depending on the steroid therapy regimen administered, the 104 patients with type 1 AIP included in this retrospective study were divided into three groups: conventional oral prednisolone (PSL) regimen (PSL group), intravenous methylprednisolone (IVMP) pulse followed by oral PSL regimen (Pulse+PSL group), and IVMP pulse-alone regimen (Pulse-alone group). We then examined the relapse rate and adverse events among the three groups.

    Results The Kaplan-Meier estimates of the relapse rate at 36 months after steroid therapy were 13.6% in the PSL group, 13.3% in the Pulse+PSL group, and 46.2% in the Pulse-alone group. The log-rank test revealed that the relapse-free survival in the Pulse-alone group was significantly shorter than that in the PSL (p=0.024) and Pulse+PSL groups (p=0.014). The exacerbation of glucose tolerance after steroid therapy was less frequently observed in the Pulse-alone group (0%) than in the PSL group (17%, p=0.050) and Pulse+PSL groups (26%, p=0.011).

    Conclusion Although treatment with IVMP pulse alone resulted in unsatisfactory relapse prevention outcomes compared with conventional steroid therapy, the IVMP pulse-alone regimen might be an alternative treatment strategy for type 1 AIP from the perspective of avoiding adverse events from steroids.

    Download PDF (346K)
  • Chiaki Kawame, Hajime Kasai, Shunya Shiohira, Toshihiko Sugiura, Yuki ...
    2023 Volume 62 Issue 20 Pages 2941-2948
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: August 02, 2023
    JOURNAL OPEN ACCESS

    Objective Venous thromboembolism (VTE) is a common complication of severe coronavirus disease 2019 (COVID-19) and is associated with its prognosis. The fibrin monomer complex (FMC), a marker of thrombin generation, is reportedly useful in diagnosing acute thrombosis. To date, there has been only one report on FMC in COVID-19, and the usefulness of FMC in COVID-19 is unknown. We therefore evaluated the frequency of VTE in non-intensive-care unit COVID-19 patients in Japan and determine the clinical utility of FMC in COVID-19.

    Methods This was a single-center retrospective study. Laboratory test results and outcomes (thrombosis and severe progression of COVID-19) were obtained via medical record review. We assessed the relationship between FMC and VTE incidence and evaluated the association between elevated FMC levels and severe progression of COVID-19.

    Patients This study included 247 patients with COVID-19 who were hospitalized between December 2020 and September 2021 and had had their levels of D-dimer and FMC measured.

    Results Of the 247 included patients, 3 (1.2%) developed VTE. All three had elevated FMC levels on admission; however, the D-dimer level was not elevated in one case on admission. The FMC level was significantly higher in the group with severe COVID-19 progression than in the group without severe progression. A multivariate analysis showed that severe progression was associated with elevated FMC levels (odds ratio, 7.40; 95% confidence interval, 2.63-22.98; p<0.001).

    Conclusion FMC can be useful for diagnosing VTE in the acute phase of COVID-19. Elevated FMC was found to be associated with severity on admission and severe progression.

    Download PDF (632K)
  • Yu Mizutani, Shinichiro Kawamoto, Michiko Takahashi, Hisayo Doi, Kumik ...
    2023 Volume 62 Issue 20 Pages 2949-2958
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 15, 2023
    JOURNAL OPEN ACCESS

    Objective High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is an effective treatment option for relapsed and refractory aggressive malignant lymphoma. However, patients frequently experience treatment-induced gastrointestinal symptoms. Synbiotics, including live microorganisms and nondigestible food ingredients, reportedly ameliorate chemotherapy-induced mucosal damage. In this study, we assessed the efficacy and safety of synbiotics in patients undergoing auto-HSCT.

    Methods This randomized, double-blinded study included patients with malignant lymphoma eligible for auto-HSCT. The patients were randomly assigned to either a synbiotic group receiving Bifidobacterium longum (BB536) and guar gum or a placebo group receiving a placebo containing dextrin. The supplements were administered twice daily from the start of conditioning chemotherapy up to 28 days after auto-HSCT. The primary endpoint was the duration of total parenteral nutrition (TPN).

    Results In total, 12 patients were included and randomized. The median duration of TPN was 15 (range, 12-33) days in the synbiotic group and 17.5 (range, 0-32) days in the placebo group. The median duration of grade ≥3 diarrhea was shorter in the synbiotic group than in then placebo group (2.5 vs. 6.5 days), as was the duration of hospital stay (31.5 vs. 43 days). The oral intake and quality of life regarding diarrhea and anorexia improved in the synbiotic group after engraftment. Synbiotic infections, including bacteremia, were not observed.

    Conclusion Synbiotics may reduce gastrointestinal toxicity, thereby reducing nutritional problems and improving the quality of life of patients undergoing auto-HSCT, without severe adverse events.

    Download PDF (825K)
  • Ichiro Deguchi, Takashi Osada, Shinichi Takahashi
    2023 Volume 62 Issue 20 Pages 2959-2964
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    Objective Despite aggressive therapeutic interventions during the acute phase of branch atheromatous disease (BAD)-type cerebral infarction, many patients, even those with a mild condition at the onset, experience neurological deterioration after hospitalization and develop serious deficits. We compared the therapeutic efficacy of multiple antithrombotic therapies for BAD between patients who received a clopidogrel loading dose (loading group; LG) and those without loading (non-loading group; NLG).

    Patients Between January 2019 and May 2022, patients with BAD-type cerebral infarction in the lenticulostriate artery admitted within 24 h of the onset were recruited. This study included 95 consecutive patients who received combination argatroban and dual antiplatelet therapy (aspirin and clopidogrel).

    Methods Patients were classified into the LG and NLG according to whether or not a loading dose of clopidogrel (300 mg) had been administered on admission. Changes in neurological severity [National Institutes of Health Stroke Scale (NIHSS) score] during the acute phase were retrospectively evaluated.

    Results There were 34 (36%) and 61 (64%) patients in the LG and NLG, respectively. On admission, the median NIHSS score was similar between the groups [LG: 2.5 (2-4) vs. NLG: 3 (2-4), p=0.771]. At 48 h following admission, the median NIHSS scores were 1 (0.25-4), and 2 (1-5) in the LG and NLG, respectively (p=0.045). Early neurological deterioration (END; defined as worsening of the NIHSS score by ≥4 points at 48 h after admission) occurred in 3% of LG and 20% of NLG patients (p=0.028).

    Conclusion Administration of a clopidogrel loading dose with combination antithrombotic therapy for BAD reduced END.

    Download PDF (450K)
CASE REPORTS
  • Kai Korekawa, Masayuki Orikasa, Atsushi Kunimitsu
    2023 Volume 62 Issue 20 Pages 2965-2969
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    An 87-year-old woman visited her primary-care doctor because of nausea and epigastric pain. Esophagogastroduodenoscopy (EGD) revealed a giant bezoar in her stomach. She was referred to our hospital after carbonated beverage dissolution proved ineffective and underwent endoscopic mechanical crushing. After crushing, the symptoms disappeared, and she began eating. Later, however, the crushed fragments reassembled in the duodenal bulb and caused intestinal obstruction. The patient underwent emergency EGD for crushing once more, and all of the fragments were extracted from the body. This case highlights the need for bezoars to be removed from the body after crushing in order to avoid reassembly.

    Download PDF (1470K)
  • Yuko Yokogawa, Tomohiro Suzuki, Hiroyuki Suzuki, Rena Nemoto, Hiroshi ...
    2023 Volume 62 Issue 20 Pages 2971-2975
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 15, 2023
    JOURNAL OPEN ACCESS

    Plexiform neurofibromas (PNs) occur in approximately 50% of patients with neurofibromatosis type 1 (NF1). PNs are rare in the abdominal cavity and especially rare in hepatobiliary lesions. A 31-year-old man with NF1 had a tumor extending along the celiac artery, superior mesenteric artery, and intrahepatic portal vein. We diagnosed him with diffuse PN based on liver tumor biopsy findings and the tumor form. Because the tumor had invaded along the intrahepatic portal vein, surgical resection was deemed difficult, and the patient was followed up with imaging studies. The patient remained asymptomatic without tumor growth.

    Download PDF (1798K)
  • Yuji Saito, Tetsu Watanabe, Taiga Ishigaki, Mashu Toyoshima, Wataru Ka ...
    2023 Volume 62 Issue 20 Pages 2977-2980
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    A 73-year-old woman presented with takotsubo syndrome with apical ballooning patterns after quarreling with her husband. Two years later, she was admitted to the hospital with chest pain after experiencing the same emotional stress. Her electrocardiogram showed different abnormalities compared to the previous event, and her left ventriculogram demonstrated takotsubo syndrome with mid-ventricular ballooning patterns. Recurrence of takotsubo syndrome with different ballooning patterns is rare. We herein report our experience with a patient who developed recurrent takotsubo syndrome with various ballooning patterns and different electrocardiographic abnormalities along with a literature review.

    Download PDF (2647K)
  • Masahiro Asakawa, Noriko Takagi, Daisuke Hamada, Yuko Yamasaki, Yutaro ...
    2023 Volume 62 Issue 20 Pages 2981-2988
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 01, 2023
    JOURNAL OPEN ACCESS

    Mineralocorticoid deficiency (MD) with hyperkalemia is an important complication of adrenalectomy in patients with primary aldosteronism (PA). We herein report a 52-year-old man with refractory hypertension, hypokalemia, and severe renal dysfunction due to PA caused by a right adrenal adenoma. His estimated glomerular filtration rate (eGFR) transiently increased immediately after adrenalectomy but then gradually declined, and he developed hyperkalemia. A postoperative endocrine examination revealed MD. Considering the patient's hypertension and severe renal dysfunction, we administered hydrocortisone instead of fludrocortisone, which improved the hyperkalemia and stopped the decline in the eGFR. Alternative therapy with hydrocortisone may be useful in such patients with MD.

    Download PDF (1848K)
  • Yumi Motokura, Akihiro Ito, Tadashi Ishida
    2023 Volume 62 Issue 20 Pages 2989-2993
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    A 79-year-old man presented with chest pain, and urinary antigen tests for Legionella pneumophila (ImmunoCatch® Legionella and Ribotest® Legionella) were negative on admission. The next day, rapid respiratory failure suggested Legionella pneumonia, and levofloxacin was added. Since a lung infiltration shadow appeared on the other side as well on day 4, non-infectious diseases were considered, and steroid therapy was started. Urinary antigen tests for Legionella pneumophila became positive on day 5. In the present case, retesting with Ribotest® Legionella, which could be negative early after the disease onset, was useful for diagnosing Legionella pneumonia, which led to the discontinuation of unnecessary steroid treatment.

    Download PDF (1465K)
  • Hikaru Mamizu, Takeshi Ohta, Kensuke Yanai, Ryo Yamazaki, Maiko Mamizu ...
    2023 Volume 62 Issue 20 Pages 2995-3000
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 22, 2023
    JOURNAL OPEN ACCESS

    We herein report a 75-year-old woman who presented with dyspnea and purpura. She was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) based on axonal damage observed in the left tibial nerve and skin and lung pathologies. Lung pathology showed IgG4-positive plasma cells, considered a complication of IgG4-related disease (IgG4-RD). Computed tomography revealed thickening of the abdominal aorta and a poor contrast area in the left kidney, which was indicative of IgG4-RD. Steroid administration improved the IgG4-RD. However, the EGPA resisted treatment; therefore, immunosuppressive drugs and mepolizumab were administered. Refractory EGPA complicated with IgG4-RD showed different treatment responses for each organ.

    Download PDF (1383K)
  • Masahiko Sumii, Masashi Namba, Kentaro Tokumo, Masami Yamauchi, Wataru ...
    2023 Volume 62 Issue 20 Pages 3001-3004
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 01, 2023
    JOURNAL OPEN ACCESS

    We herein report a patient with KRAS wild-type non-small-cell lung cancer (NSCLC) with concurrent STK11 and KEAP1 mutations. A 53-year-old man visited a local doctor with a complaint of left shoulder swelling and pain. He was diagnosed with NSCLC cT4N0M1c stage IVB. A comprehensive genome profile test revealed mutations in STK11 and KEAP1 but no KRAS mutations. The patient was refractory to radiotherapy, immunotherapy, and chemotherapy. Thus, STK11 and KEAP1 mutations can be considered resistance mutations that confer resistance to various anticancer therapies in KRAS wild-type NSCLC.

    Download PDF (1390K)
  • Nozomi Harai, Masashi Ichijo, Hiroyuki Uchinuma, Mitsuto Hanihara, Yos ...
    2023 Volume 62 Issue 20 Pages 3005-3011
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    Gaucher disease (GD) causes the accumulation of glucocerebrosides in various organs, resulting in hepatosplenomegaly, anemia, decreased platelet counts, and bone disorders. Glucosylsphingosine accumulates in the brain and causes central nervous system (CNS) disorders. GD can be classified into types I (without CNS disorders), II, and III. Substrate reduction therapy (SRT) is an oral therapy that improves patients' quality of life; however, its effect on type III GD is unknown. We administered SRT to GD types I and III patients and found it effective. Malignancy is a late complication of GD, but this is the first report of Barrett adenocarcinoma.

    Download PDF (265K)
  • Yuki Kitazaki, Osamu Yamamura, Kojiro Usui, Asako Ueno, Sayaka Sanada, ...
    2023 Volume 62 Issue 20 Pages 3013-3020
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    JOURNAL OPEN ACCESS

    Nivolumab blocks inhibitors of T-cell activation and restores antitumor immunity but promotes T-cell activity in host tissues by blocking inhibition of the T-cell function, resulting in immune-related adverse effects. We herein report an 80-year-old man presenting with nivolumab-related myasthenia gravis with anti-muscular voltage-gated potassium channel-complex (Kv1.4) antibodies. On day 29 after nivolumab administration, he simultaneously developed rapidly progressing right ptosis and left facial paralysis. Nivolumab administration was discontinued. He subsequently presented with bulbar paralysis, dyspnea, and muscle weakness and received intravenous immunoglobulin, methylprednisolone, and plasma exchange. The severity of nivolumab-related myasthenia gravis with anti-Kv1.4 antibodies presented with diverse clinical findings.

    Download PDF (1039K)
  • Takumi Tashiro, Yuichi Kira, Norihisa Maeda
    2023 Volume 62 Issue 20 Pages 3021-3025
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 15, 2023
    JOURNAL OPEN ACCESS

    A 38-year-old woman with untreated Graves' disease was admitted to our hospital because of headache and diplopia for 3 months. A neuro-ophthalmic examination showed bilateral papilledema and abducens nerve paralysis. The cerebrospinal fluid pressure was extremely high. Brain magnetic resonance imaging showed cerebral venous thrombosis in the superior sagittal and right transverse and sigmoid sinuses. Laboratory investigations revealed elevated factor VIII and von Willebrand factor levels. The patient recovered after propylthiouracil and anticoagulation therapy. We herein report a rare case of cerebral venous thrombosis with hyperthyroidism presenting as chronic isolated intracranial hypertension. Hyperthyroidism can induce a hypercoagulable state and lead to venous thromboembolism.

    Download PDF (1632K)
  • Koichi Miyashita, Yuichiro Ii, Hirofumi Matsuyama, Atsushi Niwa, Yosuk ...
    2023 Volume 62 Issue 20 Pages 3027-3031
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 15, 2023
    JOURNAL OPEN ACCESS

    We herein report a Japanese patient with myotonic dystrophy type 2 (DM2), which is rare in Japan. A 64-year-oldman had proximal muscle weakness and grip myotonia. Electromyography showed myotonic discharges, but dystrophia-myotonica protein kinase (DMPK) was negative for CTG repeats. A muscle biopsy revealed increased central nuclei, pyknotic nuclear clumps and muscle fiber atrophy, mainly in type 2 fibers, raising the possibility of DM2. The diagnosis was genetically confirmed by the abnormal CCTG repeat size in cellular nucleic acid-binding protein (CNBP) on repeat-primed polymerase chain reaction, which was estimated to be around 4,500 repeats by Southern blotting.

    Download PDF (595K)
  • Ichiro Nozaki, Akihiro Hashiguchi, Hiroshi Takashima, Yoko Yamashita, ...
    2023 Volume 62 Issue 20 Pages 3033-3036
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: February 15, 2023
    JOURNAL OPEN ACCESS

    Pathogenic variants in Gap Junction Protein Beta 1 (GJB1) cause X-linked Charcot-Marie-Tooth (CMT) disease type 1 (CMTX1), which is a common hereditary motor and sensory neuropathy. A 45-year-old man presented with progressive muscle weakness, atrophy, sensory disturbance of all limbs from childhood, and visual field defects in both eyes at 40 years old. A segregation analysis revealed a novel variant, c.173C>A (p.P58H), in the GJB1 gene. Patients with variants at codon 58 in GJB1 showed clinically varied phenotypes, ranging from demyelinating neuropathy to cerebellar ataxia. This patient may represent one of the various clinical phenotypes of GJB1 variants.

    Download PDF (406K)
  • Kiyoshi Takemoto, Makoto Kawahara, Kazuaki Atagi
    2023 Volume 62 Issue 20 Pages 3037-3041
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 01, 2023
    JOURNAL OPEN ACCESS

    Guillain-Barré syndrome (GBS) cases are generally monophasic, and recurrence is rare. However, the pathogenesis and pathophysiology of recurrent GBS remain to be fully elucidated. There are few detailed reports of patients who have been infected twice with Campylobacter jejuni and have developed GBS twice. We herein report a case of recurrent GBS in a 21-year-old man with a history of GBS caused by C. jejuni infection at 19 years old. Although our patient was reinfected with C. jejuni, several different anti-ganglioside antibodies were identified, and the clinical manifestations were more severe than those in the first GBS episode. We compared the anti-ganglioside antibodies and nerve conduction studies findings between the two GBS episodes. This case suggested that different antibodies are involved and produce different symptoms even when C. jejuni infection is the trigger in recurrent episodes.

    Download PDF (150K)
  • Ken Kunugitani, Satoshi Miura, Masanori Sawamura, Koki Mitani, Masakaz ...
    2023 Volume 62 Issue 20 Pages 3043-3046
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    The pathophysiology of idiopathic intracranial hypertension (IIH) and idiopathic normal-pressure hydrocephalus (iNPH) differs in terms of cerebrospinal fluid (CSF) pressure and imaging-related characteristics. A 51-year-old man presented with optic nerve papillary edema, visual disturbance, bilateral abducens nerve palsy, and a wide-based gait. Imaging showed characteristic findings of IIH and disproportionately enlarged subarachnoid space hydrocephalus (DESH) - characteristic of iNPH. A CSF examination revealed marked CSF hypertension. IIH with iNPH-like imaging features (DESH) was diagnosed, and ventriculoperitoneal shunt surgery was performed. Postoperatively, the visual acuity and visual field improved. This report also describes the distinct and overlapping pathophysiological mechanisms of IIH and iNPH.

    Download PDF (2808K)
  • Katsuya Nakamura, Tsuneaki Yoshinaga, Minori Kodaira, Emiko Kise, Tomo ...
    2023 Volume 62 Issue 20 Pages 3047-3051
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    We encountered a 37-year-old Japanese man with KIF1A-associated neurological disorder (KAND) who exhibited motor developmental delay, intellectual disability, and slowly progressive cerebellar ataxia, hypotonia, and optic neuropathy. Pyramidal tract signs were evident late in this case. At 30 years old, the patient developed a neurogenic bladder. A molecular diagnosis revealed a uniallelic missense de novo variant (p.L278P) of KIF1A. Serial neuroradiological studies revealed atrophy of the cerebellum at an early age, and cerebral hemisphere atrophy progressed slowly over a 22-year observation period. Our study suggests that the primary etiology of KAND may be acquired, long-standing neurodegeneration rather than congenital hypoplasia.

    Download PDF (1694K)
  • Ryuichiro Hayashi, Shigeki Yamaguchi
    2023 Volume 62 Issue 20 Pages 3053-3056
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: August 02, 2023
    JOURNAL OPEN ACCESS

    A 33-year-old woman developed paresthesia in her right thumb approximately 30 minutes after receiving the BNT162b2 (Pfizer-BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The paresthesia gradually spread to her right-side limbs and trunk, and cervical magnetic resonance imaging (MRI) revealed a localized lesion in the right dorsal column. After glucocorticoid therapy, her symptoms and MRI findings improved. Although disease developing less than 24 hours after vaccination is considered an unlikely cause of immuno-associated adverse events following vaccination, we discuss the possible mechanisms involved in early-onset central nervous system inflammation after vaccination in view of preexisting immunopathological susceptibility.

    Download PDF (1191K)
  • Hideko Akagi, Tatsuhiko Wada
    2023 Volume 62 Issue 20 Pages 3057-3062
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    JOURNAL OPEN ACCESS

    Dermatomyositis (DM) is an idiopathic inflammatory myopathy. The incidence of malignancy in DM patients is quite high. Anti-transcription intermediary factor 1-γ (anti-TIF1-γ) antibody is more prevalent in DM patients with malignancy than in those without malignancy. A 70-year-old woman developed hoarseness and difficulty swallowing. A physical examination revealed skin abnormalities. Breast cancer was found in her right breast. She was positive for anti-TIF1-γ antibody. Chemotherapy reduced the tumor size, decreased the anti-TIF1-γ antibody level, and improved her symptoms. About 2.5 years later, however, her skin symptoms worsened, and anti-TIF1-γ antibody levels increased again, and colorectal cancer was found. Treatment with endoscopic mucosal resection (EMR) improved her symptoms again. Our case suggests that the exacerbating skin symptoms and parallel increase in the anti-TIF1-γ antibody level led to the detection of a second cancer after treatment of the first cancer in this case of DM.

    Download PDF (738K)
  • Tamaki Koda, Bunki Natsumoto, Hirofumi Shoda, Keishi Fujio
    2023 Volume 62 Issue 20 Pages 3063-3067
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: July 19, 2023
    JOURNAL OPEN ACCESS

    Angioedema with eosinophilia (AE) is a rare disease of unknown etiology characterized by episodic (EAE) or nonepisodic AE (NEAE). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccines function as immunogens and intrinsic adjuvants and have been shown to be safe in large-scale trials. However, the long-term adverse reactions, especially those related to eosinophilic complications, have not been fully clarified. We herein report a case of self-limited but severe NEAE that developed in a young woman one week after receiving the second BNT162b2 mRNA vaccine. The symptoms that impaired her activities of daily living, such as edema, gradually resolved with supportive care over 10 weeks without corticosteroid treatment.

    Download PDF (288K)
  • Takanori Yamaguchi, Ryoichi Hayashi, Ryo Hanaki, Yoshinori Takahashi, ...
    2023 Volume 62 Issue 20 Pages 3069-3073
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 08, 2023
    JOURNAL OPEN ACCESS

    We herein report a three-year-old boy with septic pulmonary embolism caused by Tsukamurella paurometabola bacteremia during chemotherapy for rhabdomyosarcoma. During the interval of chemotherapy, the patient was temporarily discharged with a peripherally inserted central venous catheter but was re-admitted to the hospital with a fever on the same day. A blood culture taken at the time of re-admission showed T. paurometabola. The patient had a persistent fever, and computed tomography performed on the ninth day showed septic pulmonary embolism. We stress the importance of being aware of the possibility of septic pulmonary embolism in patients with Tsukamurella bacteremia.

    Download PDF (1540K)
  • Michiko Matsuzawa Adachi, Hitoshi Sugawara, Akira Ishii, Emiko Chiba, ...
    2023 Volume 62 Issue 20 Pages 3075-3084
    Published: October 15, 2023
    Released on J-STAGE: October 15, 2023
    Advance online publication: March 01, 2023
    JOURNAL OPEN ACCESS

    A 74-year-old woman was admitted with hypercalcemia and prolonged disturbance of consciousness. The left buttock to the anterior aspect of the left thigh was swollen and erythematous, with a collection of 1.0-cm large, firm, elastic nodules distributed in a zosteriform pattern in the L1-L4 region. Based on autopsy findings, a very rare case of Cobb syndrome was diagnosed due to a spinal vascular malformation at the Th12-L4 level and L5 vertebral hemangioma. Cobb syndrome-associated cutaneous metastasis extending along the same metamere was complicated by immunohistochemically proven parathyroid hormone-related protein-producing advanced bladder carcinoma in this case.

    Download PDF (3089K)
PICTURES IN CLINICAL MEDICINE
feedback
Top